tiprankstipranks
Advertisement
Advertisement

IRD Stock Latest News

Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
The FlyLongeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed
2d ago
IRD
LGVN
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
PremiumRatings
Analyst Maintains Buy on Opus Genetics, Reiterates $8 Price Target on Multi-Asset Retinal Disease Pipeline and Upcoming BIRD1 Data
12d ago
IRD
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
PremiumRatings
Opus Genetics Earns Buy Rating as Advancing Gene Therapy Pipeline and De-Risked LCA5 Program Support Unchanged $10 Price Target
14d ago
IRD
Opus Genetics price target lowered to $9 from $10 at RBC Capital
PremiumThe Fly
Opus Genetics price target lowered to $9 from $10 at RBC Capital
14d ago
IRD
Opus Genetics files $300M mixed securities shelf
PremiumThe Fly
Opus Genetics files $300M mixed securities shelf
15d ago
IRD
Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
PremiumRatingsAnalyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028
15d ago
IRD
Opus Genetics reports Q2 EPS (14c), consensus (16c)
Premium
The Fly
Opus Genetics reports Q2 EPS (14c), consensus (16c)
15d ago
IRD
IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
IRD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
17d ago
IRD
Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated
PremiumRatings
Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated
17d ago
IRD
Opus Genetics enrolls last patient in OPGx-LCA5 trial
PremiumThe Fly
Opus Genetics enrolls last patient in OPGx-LCA5 trial
18d ago
IRD
Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock
PremiumWeekend Updates
Opus, Cytokinetics, Albertsons, Weatherford, Paysign Shock
20d ago
ACI
IRD
CarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts
PremiumWeekend Updates
CarMax, MPLX, Opus, BJ’s, CoStar Trending With Analysts
21d ago
BJ
IRD
Opus Genetics initiated with a Buy at TD Cowen
PremiumThe FlyOpus Genetics initiated with a Buy at TD Cowen
24d ago
IRD
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
Premium
Ratings
Opus Genetics: Buy Rating Reiterated as Analyst Sees Pivotal OPGx-BEST1 Data as Key Catalyst; $10 Price Target Unchanged
1M ago
IRD
Opus Genetics sets September timeline for retinal disease trial data
Premium
The Fly
Opus Genetics sets September timeline for retinal disease trial data
1M ago
IRD
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
PremiumRatings
Yun Zhong Reiterates Buy on Opus Genetics as FDA-Backed, High-Power Phase 3 Design for OPGx-LCA5 Accelerates Path to Approval and Validates Broader Retinal Disease Pipeline
2M ago
IRD
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
PremiumRatings
Opus Genetics: FDA-Backed Phase 3 Path and Strong Early Efficacy Support Reiterated Buy on IRD with Unchanged $10 Price Target
2M ago
IRD
Opus Genetics FDA alignment further de-risks path to market, says Chardan
PremiumThe Fly
Opus Genetics FDA alignment further de-risks path to market, says Chardan
2M ago
IRD
Morning Movers: TeraWulf surges following lease agreement with Anthropic
PremiumThe Fly
Morning Movers: TeraWulf surges following lease agreement with Anthropic
2M ago
IRD
KOS
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
PremiumThe FlyOpus Genetics announces FDA alignment on OPGx-LCA5 trial
2M ago
IRD
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
Premium
Company Announcements
Opus Genetics Advances New Gene Therapy Trial for Rare Childhood Blindness
2M ago
IRD
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
Premium
The Fly
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
2M ago
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >